Phase 1/2 Investigation of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (Pioneer-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Vector Y Therapeutics
- Enrollment
- 12
- Locations
- 13
- Primary Endpoint
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)
Overview
Brief Summary
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS).
Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.
Detailed Description
All participants will receive a single injection of the study drug. During the first year of the study there will be 12 visits to the study center, including 1 overnight stay after dosing. There will be a further 4 remote visits (telephone or video call).
From Year 2-5 there will be 8 further visits. These will be every 6 months and will be either in-person at the study site or remote (telephone or video call) if needed or preferred.
Throughout the 5-year observation period, there will be up to 20 study visits to complete follow-up tests and assessments and monitor the ongoing effects of the study drug.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Capable of, and willing to, provide written informed consent and comply with study procedures, including visits to the study site and visit requirements
- •Male or female ≥ 18 years of age
- •Has a diagnosis of ALS according to the El Escorial criteria (Brooks, et al., 2000) (probable, laboratory results supported; clinically probable, clinically definite)
- •Confirmed absence of ALS caused by FUS and SOD1 gene mutations confirmed by laboratory tests.
- •A maximum of 18 months since first appearance of weakness (e.g., limb weakness, dysarthria, dysphagia, shortness of breath)
- •Erect (seated) SVC % predicted ≥ 80% at Screening
- •Treatment Research Initiative to Cure ALS (TRICALS) risk score between -2 and -6 at Screening
- •Has a reliable caregiver/partner/legal representative willing and able to support the participant in participation in the study and to give informed consent on behalf of the participant in the case that disease progression prevents the participant of giving consent (local legal rules will apply).
- •Treatment with riluzole and/or edaravone is allowed if treatment was started and has remained at a stable dose for at least 2 weeks (riluzole) or one treatment cycle (edaravone) before the Screening visit
- •Women of childbearing potential (WOCBP) and male participants with female partners who are WOCBP must agree to use highly effective contraception during and after the study. WOCBP cannot be pregnant or breastfeeding
Exclusion Criteria
- •Diagnosis of a significant CNS or peripheral nervous system disease other than ALS that may be a cause for the participant's ALS symptoms or may confound study objectives
- •Spinal, cervical, or brain MRI/MRA indicating clinically significant abnormality
- •Presence of tracheostomy and feeding tube at Screening
- •Contraindications to corticosteroid use (e.g. due to osteoporosis, uncontrolled blood pressure, diabetes or cholesterol).
- •5\. Significant concomitant disease or condition within 6 months of Screening that could pose an unacceptable safety risk to the participant or interfere with the participant's ability to comply with study procedures, e.g. heart disease, uncontrolled diabetes, liver disease, autoimmune diseases needing strong immune-suppressing drugs, cancer, etc or a current psychiatric diagnosis.
- •6\. Clinically significant abnormalities in laboratory test results at Screening for example poor liver or kidney function, abnormal clotting or infections such as Hepatitis or HIV
- •7\. Use of blood thinners (e.g., warfarin, heparin, and novel oral anticoagulants) and being unable to safely stop them before certain study procedures.
- •8\. Contraindications to imaging methods MRI, MRA, CT due to claustrophobia and/or intolerance to contrast agents.
- •9\. Contraindications to general anaesthesia (GA) or deep sedation
- •10 Positive test for illegal drugs (except prescribed medications or permitted medicinal/recreational marijuana if used responsibly)
Arms & Interventions
Gene Therapy Group 1: Dose 1 (Low Dose)
Gene Therapy: VTx-002 6 participants will receive dose 1 administered intra cisterna magna. Dosing of the first 3 participants will be staggered at specific timepoints apart and with a safety monitoring committee review of health-related information in between each participant being dosed.
VTx-002 is a single dose therapy
Drug: Optional Rescue Medication: Methylprednisolone The study doctor may administer corticosteroids (methylprednisolone or prednisone) if a participant experiences immune reactions or other side effects.
Intervention: Optional Rescue medication - Corticosteroids: Methylprednisolone (Drug)
Gene Therapy Group 2: Dose 2 (High Dose)
Gene Therapy: VTx-002 6 participants will receive dose 2 administered intra cisterna magna.
The participant dosing in group 2 will be staggered as it was in group 1. VTx-002 is a single dose therapy.
Drug: Optional Rescue Medication - Methylprednisolone The study doctor may administer corticosteroids (methylprednisolone or prednisone) if a participant experiences immune reactions or other side effects.
Intervention: Optional Rescue medication - Corticosteroids: Methylprednisolone (Drug)
Gene Therapy Group 1: Dose 1 (Low Dose)
Gene Therapy: VTx-002 6 participants will receive dose 1 administered intra cisterna magna. Dosing of the first 3 participants will be staggered at specific timepoints apart and with a safety monitoring committee review of health-related information in between each participant being dosed.
VTx-002 is a single dose therapy
Drug: Optional Rescue Medication: Methylprednisolone The study doctor may administer corticosteroids (methylprednisolone or prednisone) if a participant experiences immune reactions or other side effects.
Intervention: VTx-002 (Genetic)
Gene Therapy Group 2: Dose 2 (High Dose)
Gene Therapy: VTx-002 6 participants will receive dose 2 administered intra cisterna magna.
The participant dosing in group 2 will be staggered as it was in group 1. VTx-002 is a single dose therapy.
Drug: Optional Rescue Medication - Methylprednisolone The study doctor may administer corticosteroids (methylprednisolone or prednisone) if a participant experiences immune reactions or other side effects.
Intervention: VTx-002 (Genetic)
Outcomes
Primary Outcomes
The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Over 5 years
Assessed by reviewing the nature, incidence, severity, relatedness, seriousness and outcome of treatment emergent adverse events.
The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)
Time Frame: over 5 years
Assessed by review of Treatment Induced Peripheral Neuropathy Assessment Scale (TNAS) \*TNAS a brief participant-reported questionnaire used to measure the severity and progression of peripheral neuropathy. Each item is rated on a scale of 0 to 10, where 0 means no symptom and 10 means the symptom is as bad as it can possibly be.
The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)
Time Frame: At month 6 and month 12
Assessed by performing 4 formal interim analyses 1. 6 months after Gene Therapy Group 1 receive the single dose treatment 2. 6 months after Gene Therapy Group 2 receive the single dose treatment 3. 12 months after Gene Therapy Group 1 receive the single dose treatment 4. 12 months after Gene Therapy Group 2 receive the single dose treatment
Secondary Outcomes
- To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.(At month 6 and month 12)
- To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.(over 12 months)
- To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.(Over 5 years)
- To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.(At month 6 and month 12 *ALSFRS-R is a scale used to monitor disease progression. The 12 questions. Questions are scored from 0 to 4, with a maximum score of 48 indicating full function and a minimum score of 0 indicating significant impairment.)